FIRST PHARMACEUTICAL LABORATORY DEDICATED TO THE VAPORIZATION OF ACTIVE INGREDIENTS

The global expertise in vaporization phenomena allows the BIKY Pharma laboratory to study, develop and design vaporizable liquid formulations providing access to a new form of drug administration through the BIKY Breathe Batterie medical device.

The YouTube video is disabled to respect your choice.

BIKY Pharma...
Innovation,Vaporization,Modularity,Microdosing,Efficiency

The history of BIKY Pharma

Biotech specialized in the vaporization of active ingredients

2021
Versevrage logo
Foundation of Versevrage

With a first objective, smoking cessation by developing the first electronic tobacco and nicotine substitute by vaporization

2022
Development of NICØDIØL formulations

Our first drug candidate for smoking cessation that combines nicotine and cannabidiol (CBD)

2023
Vaporization device

Validation of our electronic drug delivery system by vaporization,
the BIKY Breathe.

Expertise

Bringing together a pioneering multidisciplinary team in the global understanding of the vaporization phenomenon, positioning us as a world leader in this expertise.

Collaboration with CIC CHUGA

The Clinical Investigation Center at Grenoble University Hospital validates our approach to smoking cessation and supports us in our clinical trials.

2024
Expansion of our therapeutic areas

Opening of capital to committed partners ensuring seamless support in internal structuring.

Openness to therapeutic cannabis

Work on liquid formulations that can be vaporized by inhalation in the context of pain management.

ia BIKY Pharma
AI integration

Development of predictive models making it possible to justify a potentiation of certain molecules through vaporization.

Versevrage becomes BIKY Pharma

Change of name for the company to be in line with the expansion of our therapeutic areas. “BIKY” being a tribute to the mother of one of the co-founders symbolized by the silhouette of Biky inside the logo! By people for people remaining the first value of society.

2025
CE marking Medical device

At the start of 2025, we obtained CE marking for our BIKY Breathe Batterie medical device.

Organ donation BIKY Pharma
Company ambassador for organ donation

It is with great pride that BIKY Pharma formalizes its commitment by becoming the first “ Company ambassador for organ donation » in Isère. Because raise awareness and talking about it today means saving lives tomorrow. More information on www.greffesplus.fr. 💚

2026
Registration on Swissdamed

Registration of the BIKY Breathe Batterie medical device on Swissdamed.

“

Sustainable and effective solutions
Provide complementary solutions in the different therapeutic areas where we are involved. Our treatments address major public health issues, in France and internationally, such as smoking cessation or pain management.
An innovative medical approach
Starting from a medical innovation based on the principle of vaporization and inhalation of active ingredients, we are opening the way towards a new form of drug administration in different therapeutic areas thanks to different kinetics and a patient approach. The objective is to potentiate a molecule through a new dosage form when this is beneficial.
A human corporate culture, based on the collective, transparency and passion
A corporate culture based on people, by people. The collective, a priority for carrying out our long-term project. Transparency, honesty, dynamism, passion in what we do and more generally, the stubborn work associated with them define the foundations of our company and guide the conduct of its founders and collaborators.

The BIKY Pharma mission

Our mission: innovate for health, between prevention, improvement and treatment
Provide an innovative and versatile solution to meet public health needs, in France and internationally. Our mission is to offer a device for vaporizing active ingredients allowing a new approach in the administration of therapeutic treatments. We firmly believe that vaporization can revolutionize the way many health problems are treated, from pain management to helping people quit smoking, but also for other innovative medical applications yet to be explored. We want to make these treatments more accessible, effective and adapted to the individual needs of patients, while helping to improve their quality of life.
 
Cutting-edge vaporization technology

Our vaporization technology is based on the development of innovative formulations and electronic devices designed to allow optimal administration of active ingredients. As pioneers of this new form of administration, we aim to integrate vaporization as a therapeutic alternative recognized and supervised by the health system. We are exploring new perspectives in order to potentiate certain molecules around our therapeutic areas such as nicotine, bronchodilators or even the main cannabinoids (CBD and THC). We are convinced that this approach can pave the way for more personalized treatments that are better tolerated by patients.

Sébastien OmbéCEO - BIKY Pharma

Billions of € of potential market
-1
drug candidates
0
potential patients
> 0 Bn

A new form of administration
for a global market

BIKY Pharma is interested in potentiating the therapeutic effects of a molecule thanks to a new form of administration by vaporization when the latter becomes best suited to treat a particular pathology.

One of the objectives is to reduce the quantity of active ingredients necessary for a treatment thanks to better release of the drug making it possible to limit side effects and cover a greater number of beneficiary patients.

Currently our areas of development cover major public health needs and issues at the international level. We optimize the distribution of active ingredients (AP) as well as the way of administering them via 4 main axes:

  • Fast kinetics
  • Improved bioavailability
  • Decreased amounts of PA
  • Differentiating patient approach

Our team

management team

Sébastien Ombé

CEO - co-founder

Linkedin Mail-bulk

Christophe Cochet

DG - Responsible pharmacist

Linkedin Mail-bulk

Cédric Verlucco

co-founder

Linkedin Mail-bulk

Caroline Bravo

Dev. project

Linkedin Mail-bulk

Scientific Advisory Committee

Dr. Mathieu Chappuy

Addictologist

Dr. Jean Perriot

Pulmonologist

Dr. Eric Blouin

Toxicologist

Jacques Le Houezec

Tobacco specialist

Dr. Christian Gov

Pain specialist

Dr. Gérard Mick

Neurologist

Thank you to all our partners

Thank you to all our collaborators

Want to be part of the adventure?

Any questions?

Contact us for more information

CONTACT US